Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. (Q36764907)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17373897%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

review article

1 reference

title

Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17373897%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17373897%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Benjamin F Johnson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17373897%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Timothy M Clay

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17373897%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Amy C Hobeika

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17373897%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Michael A Morse

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17373897%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

language of work or name

English

0 references

publication date

1 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17373897%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

27 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17373897%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17373897%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17373897%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

449-460

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17373897%20AND%20SRC:MED&resulttype=core&format=json

Anti-angiogenic treatment of gastrointestinal malignancies

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

The present and future of angiogenesis-directed treatments of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Dendritic cell-based tumor vaccines and antigen presentation attenuators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Dendritic cell-based vaccination against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Angiogenesis modulates the tumour immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Biology of vascular endothelial growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Vascular permeability factor (VPF, VEGF) in tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Isolation of a tumor factor responsible for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

VEGF as a mediator of tumor-associated immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Immature myeloid cells and cancer-associated immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Role of immature myeloid Gr-1+ cells in the development of antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Role of dendritic cells in the generation of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Neuropilin-1: a surface marker of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Dendritic cells can turn CD4+ T lymphocytes into vascular endothelial growth factor-carrying cells by intercellular neuropilin-1 transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

KDR receptor: a key marker defining hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

NF-kappaB transcription factors: critical regulators of hematopoiesis and neuronal survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Dendritic cell survival and maturation are regulated by different signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Expression of relB is required for the development of thymic medulla and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Distinct role of macrophages in different tumor microenvironments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Monocyte/macrophage infiltration in tumors: modulators of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Differential effects of statins on relevant functions of human monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Molecularly targeted therapy for gastrointestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Properties of thalidomide and its analogues: implications for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Isolation of an anti-angiogenic substance from Agaricus blazei Murill: its antitumor and antimetastatic actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Anti-angiogenic and immunomodulatory effect of the herbal medicine "Juzen-taiho-to" on malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Synergy between tumor immunotherapy and antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.449

21 January 2018

Identifiers

DOI

10.1517/14712598.7.4.449

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17373897%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference